Menopur (Menotrophin)

Menotropin contains follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). After injection, it binds to specific receptors on ovarian cells, triggering signaling pathways that promote follicle growth, estrogen production, and final maturation of the oocyte, thereby facilitating ovulation.

The dose of Menopur is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s ovarian response, underlying condition, and treatment protocol. Patients should follow the prescribing physician’s instructions and not alter the regimen on their own.

Menopur is intended for use before pregnancy to achieve conception. Its safety in established pregnancy or while breastfeeding has not been established, and it is generally not recommended for use during these periods. Women should discuss any concerns with their healthcare provider.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Menopur delivers a fixed combination of FSH and LH activity, whereas some alternatives provide only FSH (e.g., recombinant FSH) or separate LH preparations. The combined activity can simplify dosing for certain protocols, but clinicians choose the product based on individual patient response, cost, and specific treatment goals.

Menopur is supplied as a lyophilized powder for reconstitution. It must be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product label and kept refrigerated if not used immediately.

Menopur is administered by subcutaneous or intramuscular injection after reconstitution with the supplied diluent. The injection site is typically the abdomen or thigh for subcutaneous use, or the gluteal muscle for intramuscular administration. Proper aseptic technique and dosing instructions from the prescriber must be followed.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, fluid accumulation, and respiratory distress, as well as multiple pregnancy and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for early signs of these complications.

Menopur is contraindicated in individuals with known hypersensitivity to menotropin or any component of the formulation, in women with active ovarian cysts, uncontrolled thyroid disease, or severe ovarian hyperstimulation syndrome. It should also be avoided in patients for whom pregnancy is not desired without appropriate contraceptive measures.